Lianhua Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lianhua Zhu has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Yukun Luo
Department of Ultrasound, the First Medical Centre Chinese PLA General Hospital Beijing China
6 shared publications - Xiang Fei
Department of Ultrasound, The First Medical Center, Chinese PLA General Hospital, Beijing, China
5 shared publications - Jiang Bo
Department of Ultrasound, The First Medical Center, Chinese PLA General Hospital, Beijing, China
3 shared publications Ling Ren
3 shared publicationsYuzhuo Zhao
3 shared publications- Han Peng
Department of Ultrasound, The First Medical Center, Chinese PLA General Hospital, Beijing, China
2 shared publications
Latest Publications
- 1 December 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (3) , e251698
Contrast-enhanced US Evaluation of Residual Hepatocellular Carcinoma Following Lenvatinib Combined with Anti-PD-1 Antibody Downstaging Therapy
Contrast-enhanced US demonstrated a sensitivity and area under the receiver operating characteristic curve noninferior to contrast-enhanced MRI in the detection of residual hepatocellular carcinoma after lenvatinib and anti–programmed cell death protein-1 antibody therapy.
- 1 December 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (3) , e251698
Contrast-enhanced US Evaluation of Residual Hepatocellular Carcinoma Following Lenvatinib Combined with Anti-PD-1 Antibody Downstaging Therapy
Contrast-enhanced US demonstrated a sensitivity and area under the receiver operating characteristic curve noninferior to contrast-enhanced MRI in the detection of residual hepatocellular carcinoma after lenvatinib and anti–programmed cell death protein-1 antibody therapy.
- Open Access
- 1 December 2025
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 15 (12) , 12742-12753
Ultrasound molecular imaging in evaluating the severity of ischemia-reperfusion injury-induced acute kidney injury
Original Article Ultrasound molecular imaging in evaluating the severity of ischemia-reperfusion injury-induced acute kidney injury Ling Ren, Qing Song, Yuzhuo Zhao, Rui Bao, Fang Xie, Lianhua Zhu, Yukun Luo
- 1 December 2025
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 15 (12) , 12742-12753
Open AccessUltrasound molecular imaging in evaluating the severity of ischemia-reperfusion injury-induced acute kidney injury
Original Article Ultrasound molecular imaging in evaluating the severity of ischemia-reperfusion injury-induced acute kidney injury Ling Ren, Qing Song, Yuzhuo Zhao, Rui Bao, Fang Xie, Lianhua Zhu, Yukun Luo
- 10 September 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (2) , 747-756
A practical contrast-enhanced ultrasound risk prediction of gallbladder polyp: differentiation of adenoma from cholesterol polyp lesion
- 10 September 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (2) , 747-756
A practical contrast-enhanced ultrasound risk prediction of gallbladder polyp: differentiation of adenoma from cholesterol polyp lesion
- 5 February 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 967, 176391
The therapeutic effect of Picroside II in renal ischemia-reperfusion induced acute kidney injury: An experimental study
- 5 February 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 967, 176391
The therapeutic effect of Picroside II in renal ischemia-reperfusion induced acute kidney injury: An experimental study
- Open Access
- 3 January 2024
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 9 (4) , e10638
Ultrasound molecular imaging for early detection of acute renal ischemia–reperfusion injury
Background: Microcirculatory perfusion disorder and inflammatory response are critical links in acute kidney injury (AKI). We aim to construct anti‐vascular cell adhesion molecule‐1(VCAM‐1) targeted microbubbles (TM) to monitor renal microcirculatory perfusion and inflammatory response.Methods: TM carrying VCAM‐1 polypeptide was constructed by biological coupling. The binding ability of TM to human umbilical vein endothelial cells (HUVECs) was detected. Bilateral renal ischemia–reperfusion injury (IRI) models of mice were established to evaluate microcirculatory perfusion and inflammatory response using TM. Thirty‐six mice were randomly divided into six groups according to the different reperfusion time (0.5, 2, 6, 12, and 24 h) and sham‐operated group (Sham group). The correlation of TM imaging with serum and histopathological biomarkers was investigated.Results: TM has advantages such as uniform distribution, regular shape, high stability, and good biosafety. TM could bind specifically to VCAM‐1 molecule expressed by tumor necrosis factor‐alpha (TNF‐α)‐treated HUVECs. In the renal IRI‐AKI model, the area under the curve (AUC) of TM significantly decreased both in the renal cortical and medullary after 2 h of reperfusion compared with the Sham group (p < 0.05). Normalized intensity difference (NID) of TM at different reperfusion time was all higher than that of blank microbubbles (BM) and the Sham group (p < 0.05). Ultrasound molecular imaging of TM could detect AKI early before commonly used renal function markers, histopathological biomarkers, and BM imaging. AUC of TM was negatively correlated with serum creatinine (Scr), blood urea nitrogen (BUN), and Cystatin C (Cys‐C) levels, and NID of TM was linearly correlated with VCAM‐1, TNF‐α, and interleukin‐6 (IL‐6) expression (p < 0.05).Conclusions: Ultrasound molecular imaging based on TM carrying VCAM‐1 polypeptide can accurately evaluate the changes in renal microcirculatory perfusion and inflammatory response, which might be a promising modality for early diagnosis of AKI.
- 3 January 2024
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 9 (4) , e10638
Open AccessUltrasound molecular imaging for early detection of acute renal ischemia–reperfusion injury
Background: Microcirculatory perfusion disorder and inflammatory response are critical links in acute kidney injury (AKI). We aim to construct anti‐vascular cell adhesion molecule‐1(VCAM‐1) targeted microbubbles (TM) to monitor renal microcirculatory perfusion and inflammatory response.Methods: TM carrying VCAM‐1 polypeptide was constructed by biological coupling. The binding ability of TM to human umbilical vein endothelial cells (HUVECs) was detected. Bilateral renal ischemia–reperfusion injury (IRI) models of mice were established to evaluate microcirculatory perfusion and inflammatory response using TM. Thirty‐six mice were randomly divided into six groups according to the different reperfusion time (0.5, 2, 6, 12, and 24 h) and sham‐operated group (Sham group). The correlation of TM imaging with serum and histopathological biomarkers was investigated.Results: TM has advantages such as uniform distribution, regular shape, high stability, and good biosafety. TM could bind specifically to VCAM‐1 molecule expressed by tumor necrosis factor‐alpha (TNF‐α)‐treated HUVECs. In the renal IRI‐AKI model, the area under the curve (AUC) of TM significantly decreased both in the renal cortical and medullary after 2 h of reperfusion compared with the Sham group (p < 0.05). Normalized intensity difference (NID) of TM at different reperfusion time was all higher than that of blank microbubbles (BM) and the Sham group (p < 0.05). Ultrasound molecular imaging of TM could detect AKI early before commonly used renal function markers, histopathological biomarkers, and BM imaging. AUC of TM was negatively correlated with serum creatinine (Scr), blood urea nitrogen (BUN), and Cystatin C (Cys‐C) levels, and NID of TM was linearly correlated with VCAM‐1, TNF‐α, and interleukin‐6 (IL‐6) expression (p < 0.05).Conclusions: Ultrasound molecular imaging based on TM carrying VCAM‐1 polypeptide can accurately evaluate the changes in renal microcirculatory perfusion and inflammatory response, which might be a promising modality for early diagnosis of AKI.
- Open Access
- 2 November 2021
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-12
Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol
Transarterial chemoembolization (TACE) is an effective locoregional therapy in hepatocellular carcinoma (HCC). However, it is difficult to predict the tumour response (TR) of TACE intraprocedurally. The aim of this study was to predict the TR after TACE (1–3 months) in HCC patients using intraprocedural intraarterial contrast enhanced ultrasound (IA-CEUS). In this case-control study, consecutive patients who received TACE in our hospital from September 2018 to May 2019 were enrolled. IA-CEUS was performed before and after TACE. Postoperative contrast-enhanced liver MRI was performed 1–3 months after TACE as the gold standard. According to the modified Response Evaluation Criteria in Solid Tumours (mRECIST), ultrasonic manifestations were compared between the complete remission (CR) group and non-CR group by univariate and multivariate analyses. A logistic predictive model was established and validated, and its diagnostic efficiency was evaluated. Forty-four patients with sixty-one lesions were enrolled in the study. Multivariate analysis identified, the risk factors as a large lesion diameter (OR: 1.84; 95% confidence interval [CI]: 1.009, 3.080; P = 0.020), a larger dimension of non-enhancing area in superior mesenteric artery (SMA)-CEUS than the size in B-mode ultrasound preoperatively (OR: 3.379; 95% CI: 1.346,8.484; P = 0.010), presence of corona enhancement in hepatic artery (HA)-CEUS postoperatively (OR: 6.642; 95% CI: 1.214, 36.331; P = 0.029), and decreased corona enhancement thickness (per centimetre) postoperatively (OR: 0.025; 95% CI: 0.006,0.718; P = 0.025). The area under the receiver operating characteristic curve (AUROC) of the predictive model was 0.904 (95% CI: 0.804, 0.966; P < 0.001). The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 81.08, 91.67, 85.25, 93.75, and 75.86%, respectively. Leave-one-out cross-validation (LOOCV) showed that the accuracy was 77.05%. Intraprocedural IA-CEUS can be used to predict the TR in HCC patients after TACE.
- 2 November 2021
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-12
Open AccessIntraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol
Transarterial chemoembolization (TACE) is an effective locoregional therapy in hepatocellular carcinoma (HCC). However, it is difficult to predict the tumour response (TR) of TACE intraprocedurally. The aim of this study was to predict the TR after TACE (1–3 months) in HCC patients using intraprocedural intraarterial contrast enhanced ultrasound (IA-CEUS). In this case-control study, consecutive patients who received TACE in our hospital from September 2018 to May 2019 were enrolled. IA-CEUS was performed before and after TACE. Postoperative contrast-enhanced liver MRI was performed 1–3 months after TACE as the gold standard. According to the modified Response Evaluation Criteria in Solid Tumours (mRECIST), ultrasonic manifestations were compared between the complete remission (CR) group and non-CR group by univariate and multivariate analyses. A logistic predictive model was established and validated, and its diagnostic efficiency was evaluated. Forty-four patients with sixty-one lesions were enrolled in the study. Multivariate analysis identified, the risk factors as a large lesion diameter (OR: 1.84; 95% confidence interval [CI]: 1.009, 3.080; P = 0.020), a larger dimension of non-enhancing area in superior mesenteric artery (SMA)-CEUS than the size in B-mode ultrasound preoperatively (OR: 3.379; 95% CI: 1.346,8.484; P = 0.010), presence of corona enhancement in hepatic artery (HA)-CEUS postoperatively (OR: 6.642; 95% CI: 1.214, 36.331; P = 0.029), and decreased corona enhancement thickness (per centimetre) postoperatively (OR: 0.025; 95% CI: 0.006,0.718; P = 0.025). The area under the receiver operating characteristic curve (AUROC) of the predictive model was 0.904 (95% CI: 0.804, 0.966; P < 0.001). The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 81.08, 91.67, 85.25, 93.75, and 75.86%, respectively. Leave-one-out cross-validation (LOOCV) showed that the accuracy was 77.05%. Intraprocedural IA-CEUS can be used to predict the TR in HCC patients after TACE.
- Vol. 42 (6) , 922-928
[Differential diagnosis of gallbladder polypoid lesions by micro-flow imaging].
To explore the value of micro-flow imaging (MFI) in evaluating blood flow characteristics and differential diagnosis of gallbladder polypoid lesions. We retrospectively analyzed the clinical data and ultrasound images of 73 patients with gallbladder polypoid lesions, including 24 patients with pathologically confirmed neoplastic polyps (n=24) and 49 with non-neoplastic polyps (n=49). All the patients underwent conventional ultrasound, MFI and contrast enhanced ultrasound (CEUS) before cholecystectomy. The blood flow characteristics of the lesions in color Doppler flow imaging (CDFI) and MFI were compared, and the consistency of the findings by these two modalities with those of CEUS were evaluated by weighted Kappa consistency test. The diagnostic performance of MFI for gallbladder polypoid lesions was assessed. There were significant differences between MFI and CDFI in the evaluation of blood flow characteristics of gallbladder polypoid lesions (χ2=37.684, P < 0.001). MFI showed better performance than CDFI in displaying the blood flow characteristics of the polyps. The consistency in the findings was 0.118 between CDFI and CEUS and 0.816 between MFI and CEUS. The sensitivity, specificity and accuracy of MFI in distinguishing neoplastic polyps from non-neoplastic polyps were 75.00%, 93.88% and 87.67%, respectively. MFI has a good consistency with CEUS in displaying the blood flow characteristics of gallbladder polypoid lesions and can accurately distinguish neoplastic polyps from non-neoplastic polyps, thus providing new ultrasound diagnostic evidence to support clinical decisions on optimal treatments of gallbladder polypoid lesions.
- Vol. 42 (6) , 922-928
[Differential diagnosis of gallbladder polypoid lesions by micro-flow imaging].
To explore the value of micro-flow imaging (MFI) in evaluating blood flow characteristics and differential diagnosis of gallbladder polypoid lesions. We retrospectively analyzed the clinical data and ultrasound images of 73 patients with gallbladder polypoid lesions, including 24 patients with pathologically confirmed neoplastic polyps (n=24) and 49 with non-neoplastic polyps (n=49). All the patients underwent conventional ultrasound, MFI and contrast enhanced ultrasound (CEUS) before cholecystectomy. The blood flow characteristics of the lesions in color Doppler flow imaging (CDFI) and MFI were compared, and the consistency of the findings by these two modalities with those of CEUS were evaluated by weighted Kappa consistency test. The diagnostic performance of MFI for gallbladder polypoid lesions was assessed. There were significant differences between MFI and CDFI in the evaluation of blood flow characteristics of gallbladder polypoid lesions (χ2=37.684, P < 0.001). MFI showed better performance than CDFI in displaying the blood flow characteristics of the polyps. The consistency in the findings was 0.118 between CDFI and CEUS and 0.816 between MFI and CEUS. The sensitivity, specificity and accuracy of MFI in distinguishing neoplastic polyps from non-neoplastic polyps were 75.00%, 93.88% and 87.67%, respectively. MFI has a good consistency with CEUS in displaying the blood flow characteristics of gallbladder polypoid lesions and can accurately distinguish neoplastic polyps from non-neoplastic polyps, thus providing new ultrasound diagnostic evidence to support clinical decisions on optimal treatments of gallbladder polypoid lesions.